MET and non-small cell lung carcinoma: In summary, the three proteins mentioned above are most likely the important targets of the four active ingredients we screened; therefore, we speculate that these four active ingredients may have expected therapeutic effects on NSCLC and breast cancer by inhibiting the EGFR and MET (49, 50) in the following text.